JP2018525979A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525979A5 JP2018525979A5 JP2018501179A JP2018501179A JP2018525979A5 JP 2018525979 A5 JP2018525979 A5 JP 2018525979A5 JP 2018501179 A JP2018501179 A JP 2018501179A JP 2018501179 A JP2018501179 A JP 2018501179A JP 2018525979 A5 JP2018525979 A5 JP 2018525979A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- composition
- nuclease
- donor molecule
- introducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 39
- 101710163270 Nuclease Proteins 0.000 claims description 26
- 108700019146 Transgenes Proteins 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 9
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 8
- 238000003776 cleavage reaction Methods 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 230000007017 scission Effects 0.000 claims description 5
- 239000013603 viral vector Substances 0.000 claims description 5
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 4
- 102000001301 EGF receptor Human genes 0.000 claims description 4
- 108060006698 EGF receptor Proteins 0.000 claims description 4
- 108091008794 FGF receptors Proteins 0.000 claims description 4
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims description 4
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 4
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 claims description 4
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 229940123121 B-cell inhibitor Drugs 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 2
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 2
- 108010076282 Factor IX Proteins 0.000 claims description 2
- 108010054218 Factor VIII Proteins 0.000 claims description 2
- 102000001690 Factor VIII Human genes 0.000 claims description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 2
- 208000031220 Hemophilia Diseases 0.000 claims description 2
- 208000009292 Hemophilia A Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 108091008606 PDGF receptors Proteins 0.000 claims description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims description 2
- 108091008874 T cell receptors Proteins 0.000 claims description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 2
- 239000003114 blood coagulation factor Substances 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 229960004222 factor ix Drugs 0.000 claims description 2
- 229960000301 factor viii Drugs 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 102100027271 40S ribosomal protein SA Human genes 0.000 claims 1
- 108050007366 40S ribosomal protein SA Proteins 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 108010078575 mannan receptor Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020209010A JP7348160B2 (ja) | 2015-07-13 | 2020-12-17 | ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法及び組成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562191918P | 2015-07-13 | 2015-07-13 | |
| US62/191,918 | 2015-07-13 | ||
| US201562247469P | 2015-10-28 | 2015-10-28 | |
| US62/247,469 | 2015-10-28 | ||
| US201662315438P | 2016-03-30 | 2016-03-30 | |
| US62/315,438 | 2016-03-30 | ||
| PCT/US2016/042024 WO2017011519A1 (en) | 2015-07-13 | 2016-07-13 | Delivery methods and compositions for nuclease-mediated genome engineering |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020209010A Division JP7348160B2 (ja) | 2015-07-13 | 2020-12-17 | ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018525979A JP2018525979A (ja) | 2018-09-13 |
| JP2018525979A5 true JP2018525979A5 (Direct) | 2019-08-22 |
| JP6954890B2 JP6954890B2 (ja) | 2021-10-27 |
Family
ID=57758305
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501179A Active JP6954890B2 (ja) | 2015-07-13 | 2016-07-13 | ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法及び組成物 |
| JP2020209010A Active JP7348160B2 (ja) | 2015-07-13 | 2020-12-17 | ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020209010A Active JP7348160B2 (ja) | 2015-07-13 | 2020-12-17 | ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10450585B2 (Direct) |
| EP (1) | EP3322297B1 (Direct) |
| JP (2) | JP6954890B2 (Direct) |
| CN (1) | CN108024544B (Direct) |
| AU (1) | AU2016291778B2 (Direct) |
| CA (1) | CA2991301A1 (Direct) |
| WO (1) | WO2017011519A1 (Direct) |
Families Citing this family (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2853829C (en) | 2011-07-22 | 2023-09-26 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
| US20150166985A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting von willebrand factor point mutations |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
| EP3177718B1 (en) | 2014-07-30 | 2022-03-16 | President and Fellows of Harvard College | Cas9 proteins including ligand-dependent inteins |
| AU2015330699B2 (en) | 2014-10-10 | 2021-12-02 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| CA2963820A1 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11420136B2 (en) | 2016-10-19 | 2022-08-23 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| AU2016291778B2 (en) | 2015-07-13 | 2021-05-06 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| IL295616A (en) | 2015-07-31 | 2022-10-01 | Us Health | Adapted cells and treatment methods |
| WO2017053879A1 (en) | 2015-09-24 | 2017-03-30 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
| IL287319B2 (en) | 2015-10-05 | 2023-02-01 | Prec Biosciences Inc | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene |
| ES2768984T3 (es) | 2015-10-05 | 2020-06-24 | Prec Biosciences Inc | Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas |
| SG10202104041PA (en) | 2015-10-23 | 2021-06-29 | Harvard College | Nucleobase editors and uses thereof |
| KR102766526B1 (ko) | 2015-10-28 | 2025-02-13 | 상가모 테라퓨틱스, 인코포레이티드 | 간-특이적 작제물인, 인자 viii 발현 카세트 및 이의 사용 방법 |
| EP3433363A1 (en) | 2016-03-25 | 2019-01-30 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
| WO2017180694A1 (en) | 2016-04-13 | 2017-10-19 | Editas Medicine, Inc. | Cas9 fusion molecules gene editing systems, and methods of use thereof |
| PT4180519T (pt) | 2016-04-15 | 2025-09-04 | Memorial Sloan Kettering Cancer Center | Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionados |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| EP3494215A1 (en) | 2016-08-03 | 2019-06-12 | President and Fellows of Harvard College | Adenosine nucleobase editors and uses thereof |
| CN109804066A (zh) | 2016-08-09 | 2019-05-24 | 哈佛大学的校长及成员们 | 可编程cas9-重组酶融合蛋白及其用途 |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| DK3504229T3 (da) | 2016-08-24 | 2021-12-20 | Sangamo Therapeutics Inc | Regulering af genekspression ved anvendelse af manipulerede nukleaser |
| BR112019003327A2 (pt) * | 2016-08-24 | 2019-07-02 | Sangamo Therapeutics, Inc. | nucleases manipuladas de alvo específico |
| EP3519433A1 (en) | 2016-10-03 | 2019-08-07 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
| AU2017342543B2 (en) | 2016-10-14 | 2024-06-27 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| EP3529359B1 (en) | 2016-10-18 | 2023-12-13 | Regents of the University of Minnesota | Tumor infiltrating lymphocytes for use in therapy |
| WO2018115887A1 (en) * | 2016-12-21 | 2018-06-28 | Ucl Business Plc | Therapeutic cells |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| MX2019008844A (es) * | 2017-01-26 | 2019-09-10 | Sangamo Therapeutics Inc | Ingenieria de celulas b. |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| CN110662556A (zh) | 2017-03-09 | 2020-01-07 | 哈佛大学的校长及成员们 | 癌症疫苗 |
| KR20190127797A (ko) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 시토신에서 구아닌으로의 염기 편집제 |
| IL269458B2 (en) | 2017-03-23 | 2024-02-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| WO2018232356A1 (en) | 2017-06-15 | 2018-12-20 | The Regents Of The University Of California | Targeted non-viral dna insertions |
| CA3066641A1 (en) * | 2017-06-16 | 2018-12-20 | Sangamo Therapeutics, Inc. | Targeted disruption of t cell and/or hla receptors |
| WO2019006418A2 (en) * | 2017-06-30 | 2019-01-03 | Intima Bioscience, Inc. | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY |
| WO2019006330A1 (en) * | 2017-06-30 | 2019-01-03 | Indiana University Research And Technology Corporation | COMPOSITIONS AND METHODS FOR DETECTING REACTIVITY TO ALS |
| JP2020529834A (ja) | 2017-06-30 | 2020-10-15 | プレシジョン バイオサイエンシズ，インク． | Ｔ細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変ｔ細胞 |
| WO2019014564A1 (en) | 2017-07-14 | 2019-01-17 | Editas Medicine, Inc. | SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES |
| WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| JP7190096B2 (ja) * | 2017-09-18 | 2022-12-15 | 博雅▲緝▼因（北京）生物科技有限公司 | 遺伝子編集ｔ細胞及びその使用 |
| KR102883778B1 (ko) * | 2017-09-22 | 2025-11-12 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Ii형 점액다당류증의 치료를 위한 유전자 요법 |
| EP3692063A1 (en) | 2017-10-03 | 2020-08-12 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
| WO2019079347A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | USES OF BASIC EDITORS ADENOSINE |
| CN111655719A (zh) | 2017-10-27 | 2020-09-11 | 加利福尼亚大学董事会 | 内源性t细胞受体的靶向置换 |
| KR20200097760A (ko) * | 2017-12-11 | 2020-08-19 | 에디타스 메디신, 인코포레이티드 | 유전자 편집을 위한 cpf1-관련 방법 및 조성물 |
| EP3725092A4 (en) | 2017-12-14 | 2021-09-22 | FloDesign Sonics, Inc. | DRIVE AND CONTROL UNIT FOR ACOUSTIC CONVERTER |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| KR102764123B1 (ko) | 2018-04-05 | 2025-02-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | Τ 세포 수용체 및 이를 발현하는 조작된 세포 |
| MX2020010461A (es) | 2018-04-05 | 2021-01-15 | Juno Therapeutics Inc | Linfocitos t que expresan un receptor recombinante, polinucleotidos y metodos relacionados. |
| BR112020020245A2 (pt) | 2018-04-05 | 2021-04-06 | Editas Medicine, Inc. | Métodos de produzir células expressando um receptor recombinante e composições relacionadas |
| AU2019252527B2 (en) | 2018-04-12 | 2024-02-22 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| EP3814492A4 (en) | 2018-06-29 | 2022-02-23 | Wuhan Neurophth Biotechnology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
| EP3820509A1 (en) | 2018-07-09 | 2021-05-19 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| KR20210039428A (ko) | 2018-08-03 | 2021-04-09 | 상가모 테라퓨틱스, 인코포레이티드 | 인자 viii의 발현에 의한 개선된 임상 파라미터 |
| WO2020033525A1 (en) * | 2018-08-07 | 2020-02-13 | Sangamo Therapeutics, Inc. | Method for the treatment of mucopolysaccharidosis type ii |
| CN108949763A (zh) * | 2018-08-15 | 2018-12-07 | 吉林大学 | 能有效抑制猪瘟病毒感染的精确突变LamR基因及应用 |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| JP7403852B2 (ja) | 2018-08-20 | 2023-12-25 | ウーハン ニューロフス バイオテクノロジー リミテッド カンパニー | レーベル遺伝性視神経症を治療するための組成物及び方法 |
| WO2020038352A1 (en) * | 2018-08-20 | 2020-02-27 | Wuhan Neurophth Biological Technology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| JP7578590B2 (ja) | 2018-10-18 | 2024-11-06 | インテリア セラピューティクス，インコーポレーテッド | 第ｉｘ因子を発現するための組成物及び方法 |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| WO2020102578A1 (en) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc | Compositions and methods for compartment-specific cargo delivery |
| AU2019378883A1 (en) * | 2018-11-14 | 2021-06-03 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for T cell delivery |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020162978A1 (en) | 2019-02-06 | 2020-08-13 | Sangamo Therapeutics, Inc. | Method for the treatment of mucopolysaccharidosis type i |
| AU2020242032A1 (en) | 2019-03-19 | 2021-10-07 | Massachusetts Institute Of Technology | Methods and compositions for editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| SG11202111372VA (en) | 2019-05-01 | 2021-11-29 | Juno Therapeutics Inc | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods |
| MX2021013219A (es) | 2019-05-01 | 2022-02-17 | Juno Therapeutics Inc | Celulas que expresan un receptor recombinante de un locus de tgfbr2 modificado, polinucleotidos relacionados y metodos. |
| US11622547B2 (en) | 2019-06-07 | 2023-04-11 | Regeneran Pharmaceuticals, Inc. | Genetically modified mouse that expresses human albumin |
| CN114502587A (zh) * | 2019-07-30 | 2022-05-13 | 普瑞文森生物有限公司 | 通过非耗竭性b细胞抑制剂降低免疫原性的方法和组合物 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| CN113025633B (zh) | 2019-12-09 | 2024-08-27 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 |
| JP2023525304A (ja) | 2020-05-08 | 2023-06-15 | ザ ブロード インスティテュート，インコーポレーテッド | 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物 |
| CN115835873A (zh) | 2020-05-13 | 2023-03-21 | 朱诺治疗学股份有限公司 | 用于产生表达重组受体的供体分批细胞的方法 |
| JP2023531531A (ja) | 2020-06-26 | 2023-07-24 | ジュノ セラピューティクス ゲーエムベーハー | 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法 |
| JP2023549780A (ja) | 2020-11-04 | 2023-11-29 | ジュノー セラピューティクス インコーポレイテッド | 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法 |
| PE20241173A1 (es) | 2021-10-14 | 2024-05-28 | Arsenal Biosciences Inc | Celulas inmunitarias que tienen arnhc coexpresados y sistemas de compuerta logica |
| WO2023081900A1 (en) | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods |
| WO2023122038A1 (en) * | 2021-12-20 | 2023-06-29 | Washington University | Methods and compositions for improved genetic therapies of multigenic diseases |
| JP2025522292A (ja) | 2022-05-25 | 2025-07-15 | メタゲノミ，インク． | 肝酵素発現の補充 |
| EP4615960A1 (en) | 2022-11-09 | 2025-09-17 | C3S2 GmbH | Methods for manufacturing engineered immune cells |
| JP2026504491A (ja) | 2023-02-03 | 2026-02-05 | ツェー３エス２ ゲーエムベーハー | 操作された免疫細胞の非ウイルス的製造のための方法 |
| WO2024229281A1 (en) * | 2023-05-02 | 2024-11-07 | City Of Hope | Adeno-associated virus compositions and methods of use thereof |
| WO2025096638A2 (en) | 2023-10-30 | 2025-05-08 | Turnstone Biologics Corp. | Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same |
| WO2025117858A1 (en) * | 2023-11-28 | 2025-06-05 | Metagenomi, Inc. | Supplementation of liver enzyme expression |
| WO2025212519A1 (en) | 2024-04-01 | 2025-10-09 | Moonlight Bio, Inc. | Dll3 binding proteins and uses thereof |
| WO2025235851A1 (en) | 2024-05-10 | 2025-11-13 | Juno Therapeutics, Inc. | Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US255250A (en) | 1882-03-21 | Whistling toy | ||
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US5422251A (en) | 1986-11-26 | 1995-06-06 | Princeton University | Triple-stranded nucleic acids |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
| US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
| US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
| US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| CA2181548C (en) | 1994-01-18 | 2009-11-03 | Carlos F. Barbas, Iii | Zinc finger protein derivatives and methods therefor |
| US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| WO1995025809A1 (en) | 1994-03-23 | 1995-09-28 | Ohio University | Compacted nucleic acids and their delivery to cells |
| US5585245A (en) | 1994-04-22 | 1996-12-17 | California Institute Of Technology | Ubiquitin-based split protein sensor |
| GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
| AU698152B2 (en) | 1994-08-20 | 1998-10-22 | Gendaq Limited | Improvements in or relating to binding proteins for recognition of DNA |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
| GB2338237B (en) | 1997-02-18 | 2001-02-28 | Actinova Ltd | In vitro peptide or protein expression library |
| US6342345B1 (en) | 1997-04-02 | 2002-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by reporter subunit complementation |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
| ATE466952T1 (de) | 1998-03-02 | 2010-05-15 | Massachusetts Inst Technology | Poly-zinkfinger-proteine mit verbesserten linkern |
| US6140815A (en) | 1998-06-17 | 2000-10-31 | Dover Instrument Corporation | High stability spin stand platform |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| CA2349951A1 (en) * | 1998-11-10 | 2000-05-18 | Ludwig Institute For Cancer Research | Platelet-derived growth factor d, dna coding therefor, and uses thereof |
| US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
| US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
| US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
| DE60023936T2 (de) | 1999-12-06 | 2006-05-24 | Sangamo Biosciences Inc., Richmond | Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen |
| KR20020086508A (ko) | 2000-02-08 | 2002-11-18 | 상가모 바이오사이언스 인코포레이티드 | 약물 발견용 세포 |
| US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
| EP1295463A4 (en) | 2000-05-16 | 2005-12-14 | Comsonics Inc | DEVICE AND METHOD FOR DETERMINING THE LOCATION OF SIGNAL ENTRY |
| AU2001263155A1 (en) | 2000-05-16 | 2001-11-26 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| US20030003583A1 (en) * | 2001-06-08 | 2003-01-02 | Raphael Hirsch | Regulation of transgene expression following AAV transduction |
| AU2002336373A1 (en) | 2001-08-20 | 2003-03-03 | The Scripps Research Institute | Zinc finger binding domains for cnn |
| US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
| BRPI0307383B1 (pt) | 2002-01-23 | 2019-12-31 | The Univ Of Utah Research Foundation | método de recombinação genética direcionada em célula de planta hospedeira |
| EP1504092B2 (en) | 2002-03-21 | 2014-06-25 | Sangamo BioSciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
| CA2497913C (en) | 2002-09-05 | 2014-06-03 | California Institute Of Technology | Use of chimeric nucleases to stimulate gene targeting |
| GB0312086D0 (en) * | 2003-05-27 | 2003-07-02 | Novartis Ag | Organic compounds |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| EP1737498A2 (en) | 2004-04-08 | 2007-01-03 | Sangamo Biosciences Inc. | Zinc finger proteins for treatment of neuropathic pain |
| AU2005232665B2 (en) | 2004-04-08 | 2010-05-13 | Sangamo Therapeutics, Inc. | Methods and compositions for treating neuropathic and neurodegenerative conditions |
| AU2005244751A1 (en) * | 2004-04-16 | 2005-12-01 | Genentech, Inc. | Method for augmenting B cell depletion |
| CA2579677A1 (en) | 2004-09-16 | 2006-03-30 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
| CA2607104A1 (en) | 2005-05-05 | 2006-11-16 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Sequence enabled reassembly (seer) - a novel method for visualizing specific dna sequences |
| CA2615532C (en) | 2005-07-26 | 2016-06-28 | Sangamo Biosciences, Inc. | Targeted integration and expression of exogenous nucleic acid sequences |
| US20090263900A1 (en) | 2008-04-14 | 2009-10-22 | Sangamo Biosciences, Inc. | Linear donor constructs for targeted integration |
| EP2484758B1 (en) | 2005-10-18 | 2013-10-02 | Precision Biosciences | Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity |
| JP5266210B2 (ja) | 2006-05-25 | 2013-08-21 | サンガモ バイオサイエンシズ インコーポレイテッド | 改変開裂ハーフドメイン |
| ES2378333T3 (es) | 2006-05-25 | 2012-04-11 | Sangamo Biosciences, Inc. | Métodos y composiciones para la inactivación de genes |
| US8110379B2 (en) | 2007-04-26 | 2012-02-07 | Sangamo Biosciences, Inc. | Targeted integration into the PPP1R12C locus |
| US8790345B2 (en) | 2007-08-21 | 2014-07-29 | Zimmer, Inc. | Titanium alloy with oxidized zirconium for a prosthetic implant |
| US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
| KR20160015400A (ko) | 2008-08-22 | 2016-02-12 | 상가모 바이오사이언스 인코포레이티드 | 표적화된 단일가닥 분할 및 표적화된 통합을 위한 방법 및 조성물 |
| KR101297192B1 (ko) | 2008-11-10 | 2013-08-19 | 삼성전자주식회사 | 화상형성장치, 칩, 및, 칩 패키지 |
| EP2359134B1 (en) | 2008-11-17 | 2014-06-04 | Koninklijke Nederlandse Akademie van Wetenschappen | Methods for identifying modulating compounds of lymphangiogenesis, means therefore, compounds and uses thereof |
| JP5681114B2 (ja) | 2008-12-04 | 2015-03-04 | サンガモ バイオサイエンシーズ， インコーポレイテッド | 亜鉛フィンガーヌクレアーゼを使用したラットのゲノム編集 |
| BRPI0922641B1 (pt) | 2008-12-17 | 2021-10-26 | Dow Agrosciences Llc | Método de integração de uma ou mais sequências de ácido nucleico exógenas no genoma de uma célula vegetal |
| EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| PT2534173T (pt) | 2010-02-08 | 2019-10-31 | Sangamo Therapeutics Inc | Semidomínios de clivagem manipulados |
| EP2660318A1 (en) | 2010-02-09 | 2013-11-06 | Sangamo BioSciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| AU2011235890B2 (en) | 2010-04-02 | 2014-07-31 | Ceregene, Inc. | Methods for treating Parkinson's disease and other disorders of dopaminergic neurons of the brain |
| CA2796600C (en) | 2010-04-26 | 2019-08-13 | Sangamo Biosciences, Inc. | Genome editing of a rosa locus using zinc-finger nucleases |
| LT2566972T (lt) | 2010-05-03 | 2020-03-10 | Sangamo Therapeutics, Inc. | Kompozicijos, skirtos cinko pirštu modulių susiejimui |
| EP3156062A1 (en) | 2010-05-17 | 2017-04-19 | Sangamo BioSciences, Inc. | Novel dna-binding proteins and uses thereof |
| WO2012012667A2 (en) | 2010-07-21 | 2012-01-26 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a hla locus |
| US8808684B2 (en) * | 2010-09-10 | 2014-08-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Epidermal growth factor receptor (EGFR) and methods of use in adenoviral-associated virus type 6 (AAV6) transduction |
| US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
| IL293650B2 (en) | 2011-09-21 | 2024-10-01 | Sangamo Therapeutics Inc | Methods and compositions for regulation of transgene expression |
| JP6188703B2 (ja) | 2011-10-27 | 2017-08-30 | サンガモ セラピューティクス， インコーポレイテッド | Ｈｐｒｔ遺伝子座を修飾するための方法および組成物 |
| JP6144691B2 (ja) | 2011-11-16 | 2017-06-07 | サンガモ セラピューティクス， インコーポレイテッド | 修飾されたｄｎａ結合タンパク質およびその使用 |
| CN102633883B (zh) * | 2012-02-24 | 2014-06-25 | 上海白泽生物科技有限公司 | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 |
| JP6559063B2 (ja) | 2012-05-07 | 2019-08-14 | サンガモ セラピューティクス， インコーポレイテッド | 導入遺伝子のヌクレアーゼ媒介標的化組み込みのための方法および組成物 |
| PL2855667T3 (pl) * | 2012-05-25 | 2024-03-25 | Cellectis | Sposoby uzyskiwania metodami inżynierii allogenicznych i opornych na immunosupresję limfocytów t do immunoterapii |
| US10648001B2 (en) | 2012-07-11 | 2020-05-12 | Sangamo Therapeutics, Inc. | Method of treating mucopolysaccharidosis type I or II |
| CA2886684C (en) * | 2012-10-10 | 2023-09-19 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
| JP2016500254A (ja) | 2012-12-05 | 2016-01-12 | サンガモ バイオサイエンシーズ， インコーポレイテッド | 代謝疾患の調節のための方法および組成物 |
| WO2014089541A2 (en) | 2012-12-07 | 2014-06-12 | Haplomics, Inc. | Factor viii mutation repair and tolerance induction |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| EP3730615A3 (en) | 2013-05-15 | 2020-12-09 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a genetic condition |
| US9999206B2 (en) * | 2013-07-25 | 2018-06-19 | Utah State University | Model and method for a transgenic bovidae expressing cardiac fibrosis and associated pathology |
| CN105874071B (zh) | 2013-12-09 | 2020-04-14 | 桑格摩生物科学股份有限公司 | 基因组工程化的方法和组合物 |
| JP6606088B2 (ja) | 2014-02-24 | 2019-11-13 | サンガモ セラピューティクス， インコーポレイテッド | ヌクレアーゼ媒介性標的化組み込みのための方法および組成物 |
| US20170049887A1 (en) | 2014-04-25 | 2017-02-23 | University Of Florida Research Foundation, Inc. | Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus |
| BR112016025849A2 (pt) | 2014-05-08 | 2017-10-17 | Chdi Foundation Inc | métodos e composições para o tratamento da doença de huntington |
| WO2016014794A1 (en) | 2014-07-25 | 2016-01-28 | Sangamo Biosciences, Inc. | Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells |
| US9616090B2 (en) | 2014-07-30 | 2017-04-11 | Sangamo Biosciences, Inc. | Gene correction of SCID-related genes in hematopoietic stem and progenitor cells |
| AU2016291778B2 (en) | 2015-07-13 | 2021-05-06 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| IL287319B2 (en) * | 2015-10-05 | 2023-02-01 | Prec Biosciences Inc | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene |
| KR102766526B1 (ko) | 2015-10-28 | 2025-02-13 | 상가모 테라퓨틱스, 인코포레이티드 | 간-특이적 작제물인, 인자 viii 발현 카세트 및 이의 사용 방법 |
-
2016
- 2016-07-13 AU AU2016291778A patent/AU2016291778B2/en active Active
- 2016-07-13 CN CN201680052559.6A patent/CN108024544B/zh active Active
- 2016-07-13 JP JP2018501179A patent/JP6954890B2/ja active Active
- 2016-07-13 WO PCT/US2016/042024 patent/WO2017011519A1/en not_active Ceased
- 2016-07-13 CA CA2991301A patent/CA2991301A1/en active Pending
- 2016-07-13 US US15/208,997 patent/US10450585B2/en active Active
- 2016-07-13 EP EP16825084.3A patent/EP3322297B1/en active Active
-
2019
- 2019-09-06 US US16/562,891 patent/US20200102577A1/en not_active Abandoned
-
2020
- 2020-12-17 JP JP2020209010A patent/JP7348160B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018525979A5 (Direct) | ||
| JP7348160B2 (ja) | ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法及び組成物 | |
| Mangeot et al. | Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins | |
| JP6818720B2 (ja) | カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法 | |
| US11186825B2 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting POU2AF1 | |
| US10280402B2 (en) | Immune-compatible cells created by nuclease-mediated editing of genes encoding HLA | |
| US11180730B2 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting GATA3 | |
| JP6722176B2 (ja) | 造血幹細胞におけるヌクレアーゼ媒介性ゲノム工学および補正のための方法および組成物 | |
| JP2024001104A (ja) | 改変された細胞および治療の方法 | |
| US20190100801A1 (en) | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures | |
| JP2022531231A (ja) | Ｃｄ８改変ｔ細胞療法を使用するがんの治療のための組成物及び方法 | |
| Rosigkeit et al. | Monitoring translation activity of mRNA-loaded nanoparticles in mice | |
| JP2018171075A (ja) | 改変されたカスパーゼポリペプチドおよびその使用 | |
| JP2018536390A (ja) | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ | |
| Meissner et al. | Immune editing: overcoming immune barriers in stem cell transplantation | |
| EP3314020A1 (en) | Tumor and microenvironment gene expression, compositions of matter and methods of use thereof | |
| JP2024045297A (ja) | 低／最小操作による遺伝子改変細胞の製造 | |
| JP2016539627A5 (Direct) | ||
| US20230000912A1 (en) | Genetic, developmental and micro-environmental programs in idh-mutant gliomas, compositions of matter and methods of use thereof | |
| KR102741572B1 (ko) | 조직에서 코딩 리보핵산의 표적화된 전달, 발현 및 조절을 위한 조성물 및 방법 | |
| WO2022256448A2 (en) | Compositions and methods for targeting, editing, or modifying genes | |
| Zirger et al. | Immune-mediated loss of transgene expression from virally transduced brain cells is irreversible, mediated by IFNγ, perforin, and TNFα, and due to the elimination of transduced cells | |
| JP2023546300A (ja) | 細胞治療のための方法および組成物 | |
| Zheng et al. | Engineering of human mesenchymal stem cells resistant to multiple natural killer subtypes | |
| JP2025518552A (ja) | 細胞を操作するための組成物及び方法 |